Borean Pharma AS, (Aarhus, Denmark) has established an extended and coherent proprietary protein  technology platform that allows it to use tetranectin (a native human plasma and tissue protein) as a vehicle for the creation of advanced fully human antibody analogue products, readily tailored to meet  specific therapeutic needs.